Trial reportJournal of applied oral science : revista FOB2021
Botulinum toxin type A and acupuncture for masticatory myofascial pain: a randomized clinical trial.
Trial report in Journal of applied oral science : revista FOB, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05605886 (The Effect of Botulinum Toxin A in Patients With Myofascial Pain Dysfunction Syndrome With and Without Zinc Supplementation), which is not on this map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of Botulinum Toxin A in Patients With Myofascial Pain Dysfunction Syndrome With and Without Zinc Supplementation (Randomized Controlled Trial)
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Botulinum Toxin Type A for Myogenous Temporomandibular Disorders, Focusing on the Duration of Clinical Effects and Dosage Parameters: A Systematic Review.Head & face medicine · 2026Pooled it
- Botulinum Toxin and Percutaneous Needle Electrolysis for the Treatment of Chronic Masticatory Myalgia.Toxins · 2023Trial
- Trial
- Observational
- Comparison and ranking of interventions for temporomandibular disorders-myofascial pain syndrome: a Bayesian network meta-analysis based on randomized controlled trials.BMC oral health · 2026Article
- Central and Peripheral Sensitization in Temporomandibular Disorders: Proposed Mechanisms of Botulinum Toxin Therapy.Toxins · 2026Review
- Multimodal Approaches in the Management of Temporomandibular Disorders: A Narrative Review.Journal of clinical medicine · 2025Review
- Pioneering pain management with botulinum toxin type A: From anti-inflammation to regenerative therapies.Heliyon · 2025Review
- Examination of Information Quality on Public Instagram Profiles Regarding Botulinum Toxin for Bruxism: A Study in São Paulo State, Brazil.Journal of clinical and experimental dentistry · 2024Article
- Effects of botulinum toxin type A in patients with painful temporomandibular joint disorders: a systematic review and meta-analysis.Annals of medicine and surgery (2012) · 2024Review
- Analysis of the Use of Sample Size and Effect Size Calculations in a Temporomandibular Disorders Randomised Controlled Trial-Short Narrative Review.Journal of personalized medicine · 2024Review
- Effect of Facial Acupuncture Stimulation: MRI-Based Masseter Muscle Volume Analysis and Questionnaire Evaluation.Aesthetic surgery journal. Open forum · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBoNT-A has been widely used for TMD therapy. However, the potential benefits compared to dry needling techniques are not clear.
objectivethis study aimed to compare the immediate effects of botulinum toxin type A (BoNT-A) injections and Acupuncture in myofascial temporomandibular disorders (TMD) patients. METHODOLOGY: 54 women were divided into three groups (n=18). AC patients received four sessions of traditional acupuncture, being one session/week during 20-min. BoNT-A patients were bilaterally injected with 30U and 10U in masseter and anterior temporal muscles, respectively. Moreover, a control group received saline solution (SS) in the same muscles. Self-perceived pain was assessed by visual analog scale, while pressure pain threshold (PPT) was verified by a digital algometer. Electromyographic evaluations (EMG) of anterior temporal and masseter muscles were also measured. All variables were assessed before and 1-month after therapies. The mixed-design two-way repeated measures ANOVA and Tukey's post-hoc tests were used for analysis, considering a=0.05.
resultsSelf-perceived pain decreased in all groups after one month of therapy (P<.001). BoNT-A was not better than AC in pain reduction (P=0.05), but both therapies were more effective in reducing pain than SS (P<0.05). BoNT-A was the only treatment able to improve PPT values (P<0.05); however, a severe decrease of EMG activity was also found in this group, which is considered an adverse effect.
conclusionafter one month of follow-up, all therapies reduced the self-perceived pain in myofascial TMD patients, but only BoNT-A enhanced PPT yet decreased EMG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.